Market capitalization | $166.77b |
Enterprise Value | $221.08b |
PER (TTM) P/E ratio | 44.46 |
EV/FCF (TTM) EV/FCF | 31.15 |
EV/Sales (TTM) EV/Sales | 7.53 |
P/S ratio (TTM) P/S ratio | 5.68 |
P/B ratio (TTM) P/B ratio | 33.21 |
Dividend yield | 2.74% |
Last dividend (FY23) | $8.52 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
29 Analysts have issued a Amgen forecast:
29 Analysts have issued a Amgen forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 6,717 6,717 |
3%
3%
|
|
Depreciation and Amortization | 3,885 3,885 |
19%
19%
|
|
Stock Compensation | 431 431 |
7%
7%
|
|
Operating Cash Flow | 8,471 8,471 |
13%
13%
|
|
Investments | 1,112 1,112 |
19%
19%
|
|
Dividend Paid | 4,556 4,556 |
9%
9%
|
|
Free Cash Flow | 7,359 7,359 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Head office | United States |
CEO | Robert Bradway |
Employees | 26,700 |
Founded | 1980 |
Website | www.amgen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.